Baxter International (BAX) to Release Earnings on Thursday

Baxter International (NYSE:BAX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $0.53 per share and revenue of $2.8248 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Baxter International Stock Performance

Shares of BAX stock opened at $21.73 on Tuesday. The stock has a 50-day simple moving average of $19.63 and a 200 day simple moving average of $21.39. The stock has a market capitalization of $11.17 billion, a P/E ratio of -32.92, a P/E/G ratio of 1.26 and a beta of 0.59. Baxter International has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The company has a quick ratio of 1.18, a current ratio of 1.84 and a debt-to-equity ratio of 1.21.

Hedge Funds Weigh In On Baxter International

A number of large investors have recently made changes to their positions in the business. Imprint Wealth LLC acquired a new stake in shares of Baxter International during the third quarter worth approximately $27,000. MUFG Securities EMEA plc purchased a new stake in Baxter International in the 2nd quarter worth approximately $46,000. Parallel Advisors LLC boosted its stake in shares of Baxter International by 113.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,971 shares of the medical instruments supplier’s stock valued at $90,000 after buying an additional 2,109 shares during the period. United Capital Financial Advisors LLC grew its holdings in shares of Baxter International by 19.2% during the 3rd quarter. United Capital Financial Advisors LLC now owns 10,539 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 1,694 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Baxter International by 21.4% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 4,293 shares during the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on BAX. Jefferies Financial Group dropped their target price on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, October 30th. The Goldman Sachs Group lifted their target price on Baxter International from $22.00 to $23.00 and gave the stock a “neutral” rating in a report on Friday, January 9th. TD Cowen reiterated a “hold” rating on shares of Baxter International in a research report on Thursday, October 30th. Morgan Stanley cut their price objective on Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a report on Tuesday, December 2nd. Finally, Barclays decreased their target price on shares of Baxter International from $36.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $21.40.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.